A small number of case reports of steatorrhoea after allogeneic BMT have been published, but the incidence and natural history of this complication have not been defined. We reviewed the incidence of steatorrhoea in 184 consecutive allograft recipients surviving at least 100 days. Steatorrhoea was documented in five patients, a median of 5.5 months (range 4-14) post-transplant. All patients had recent or concomitant acute gut or liver graft versus host disease (GVHD). The probability of developing steatorrhoea by 2 years post-transplant was 3.3% (95% confidence interval (CI) 72.9%) in the group overall, rising to 4.8% (CI 74.2%) in patients with acute and/or extensive chronic GVHD. All patients responded clinically to pancreatic enzyme supplements. While these observations are consistent with previously reported autopsy data suggesting that GVHD of the exocrine pancreas is likely to be the predominant underlying pathological process, in two patients concomitant small bowel or hepatic dysfunction may have contributed to the severity of steatorrhoea. Enzyme supplements were subsequently ceased in three patients without return of steatorrhoea, suggesting that the process is usually reversible. Our data demonstrate that steatorrhoea is not an infrequent complication in the 2 years postallograft, particularly in patients with GVHD.
Steatorrhoea is a rarely reported complication of allogeneic BMT. [1] [2] [3] While the condition may respond to pancreatic enzyme replacement, it is not clear from the limited literature whether steatorrhoea is solely because of pancreatic insufficiency, or whether in some cases cholestatic liver disease or small bowel dysfunction may contribute. In addition, the role of graft versus host disease (GVHD) and/ or drug-induced pancreatitis in the development of pancreatic insufficiency has not been clearly delineated. The incidence and natural history of steatorrhoea in this context is also unknown, in particular the necessity for ongoing enzyme replacement. To evaluate these issues, we reviewed data from our transplant unit over a 5 year period and combined our experience with the reported literature.
Study design
Eligible patients were those who underwent allogeneic BMT at our institution between January 1996 and June 2001 and survived at least 100 days. The minimum follow-up period in surviving patients was 6 months. All patients with chronic diarrhoea (duration more than 2 weeks) and negative stool examination (tested for pathogenic bacteria and ova, cysts and parasites) underwent upper and/or lower gastrointestinal biopsies looking for GVHD by histology and cytomegalovirus by immunohistochemistry. Three-day faecal fat collections, on a diet of 100 g fat per day where tolerated, were performed in addition if the history was suggestive of steatorrhoea, or in patients with persistent, otherwise unexplained diarrhoea.
Results
A total of 184 patients were eligible, 42 of whom underwent at least one upper and/or lower endoscopy for investigation of gastrointestinal symptoms. All 42 patients had stool microscopy and culture; 10 also underwent faecal fat collections. Five had normal (o6 g/day) or minimally elevated (6-8 g/day) levels, while the other five patients had markedly elevated levels. Steatorrhoea was documented at a median of 5.5 months (range 4-14 months) posttransplant. The probability of developing steatorrhoea by 2 years post-transplant was 3.3% (95% confidence intervals 2-9%) in the whole study population and 4.8% (74.2%) in patients with previous or current grade 2-4 acute and/or extensive chronic GVHD (Figure 1 ).
The details of faecal fat results prior to, during and after pancreatic enzyme replacement therapy in these patients are summarised in Table 1 . The results of recent (all within three months) or concomitant liver or gastrointestinal biopsies, small bowel series and liver function tests are detailed in Table 2 . Patient no. 1 had evidence of concomitant small bowel GVHD on the basis of an abnormal duodenal biopsy and small bowel series. The remaining four patients had no clear evidence of small bowel GVHD on the basis of a normal duodenal biopsy (nos. 3 and 4) and/or normal small bowel series (nos. 2, 4 and 5). The transit time from stomach to caecum was within the normal range. Three patients had biopsy-proven moderate to severe liver GVHD. Only one patient (no. 4), however, had markedly abnormal liver biochemistry at the time of diagnosis of steatorrhoea. None of four patients who had an abdominal ultrasound or CT scan had evidence of pancreatic atrophy or calcification to suggest previous pancreatitis.
All five patients received pancreatic enzyme replacement therapy (Pancrease, Janssen-Cilag, Australia, containing lipase 5600 BP units, protease 350 BP units and amylase 3200 BP units) at a median dose of six capsules (range 1-5) daily and responded clinically with reduction in diarrhoea, darkening of the stool and weight gain. Four patients had been taking prednisolone and either cyclosporin or tacrolimus for at least 2 months prior to the diagnosis of steatorrhoea and continued immunosuppressive therapy during treatment with Pancrease. The remaining patient (no. 4) commenced cyclosporin and steroids concomitant with Pancrease. Faecal fat levels were measured during therapy in two patients, substantially falling in one (no. 4), in the context of improved, but persistently abnormal liver biochemistry (ALP 225 IU/l, gGT 172 IU/l, ALT 76 IU/l, bilirubin 5 mmol/l). Conversely, high faecal fat excretion persisted in the other (no. 5) in the absence of laboratory evidence of small bowel dysfunction (B 12 , folate and ferritin levels, clotting profile and duodenal biopsy were normal) and despite normalisation of liver function. As this patient achieved a clinical response to a relatively low dose of Pancrease, a therapeutic trial of higher dose supplementation was not given. Three patients (nos. 2-4) subsequently ceased enzyme replacement after 8-37 months, with no clinical or laboratory evidence of recurrent steatorrhoea. Bilirubin (normal range 0-19 mmol/l); ALP=alkaline phosphatase (normal range 0-120 iU/l); ALT=alanine aminotransferase (normal range 0-55 IU/l); albumin: normal range 35-50 g/l; a Time for barium to travel from stomach to caecum; normal time is less than 4-5 h. b Tested 3 months prior to diagnosis of steatorrhoea, at the time of liver biopsy.
Discussion
In the absence of infection, possible causes of steatorrhoea in allograft recipients include pancreatic insufficiency, small bowel dysfunction and liver disease. The rapid clinical response to pancreatic enzyme replacement in our patients is consistent with a probable component of pancreatic insufficiency. That this is likely to reflect GVHD of the exocrine pancreas is supported by the results of a review of pancreatic histology in 26 patients undergoing autopsy within 3 months of marrow transplantation. 4 Four of 14 with recent systemic acute GVHD had epithelial cellular atypia with a lymphocytic infiltrate in exocrine ducts, pathological changes consistent with GVHD. In several of these cases, there was mucosal ulceration and haemorrhage into the duct lumen. Ductal lesions were not seen in the absence of GVHD affecting the skin, liver or gut. Acini in severely affected areas were damaged. Ductal lesions were not seen in 12 other patients without GVHD elsewhere. There was no evidence of endocrine cell damage; consistent with this, none of the five patients in our report were diabetic at the time of diagnosis of steatorrhoea or subsequently.
We do not believe that small bowel dysfunction secondary to GVHD was a significant factor in the development of steatorrhoea in most of our patients. In the healthy small intestine, absorption of fat occurs predominantly in the duodenum and proximal jejunum, but if proximal small intestinal function is impaired, fat absorption can also occur in the ileum. Thus, one would expect there to have been extensive involvement of the small intestinal mucosa by GVHD (ie involving duodenum, jejunum and ileum) to cause the levels of steatorrhoea observed in our patients. In only one patient (no. 1) was there biopsy or radiological evidence of small bowel disease. This patient had moderate to severe GVHD on duodenal and colonic biopsy, and extensive inflammatory change and ileal strictures demonstrated radiologically. Ileal involvement by GVHD might result in impairment of fat solubilisation and absorption because of bile acid malabsorption and depletion of the bile acid pool. Increases in hepatic synthesis of bile acids can compensate for intestinal losses; thus, it is only in the presence of extensive ileal disease or resection that the jejunal bile acid concentrations are likely to fall sufficiently to cause steatorrhoea. 5 Intestinal hypomotility leading to bacterial regrowth is a cause of diarrhoea in systemic diseases such as scleroderma. The absence of small bowel GVHD and normal transit times, however, would argue against hypomotility as a factor contributing to steatorrhoea in our patients.
Another possible cause of steatorrhoea in transplant patients is cholestatic liver disease. While faecal fat excretion is less than 15 g/day in most patients with steatorrhoea and liver disease, it exceeds 30 g/day in approximately 10% of patients with cirrhosis, 6 with the highest levels occurring in patients with cholestatic liver disease. Fat malabsorption in this context probably reflects impaired bile-acid uptake, synthesis and secretion. Of note, three of our patients had recent biopsy-proven hepatic GVHD and abnormal liver function. It is unlikely, however, that reduced hepatic excretion of bile-acids contributed significantly to the malabsorption in two of these cases (nos. 2 and 5), in whom steatorrhoea occurred in the context of only modestly raised liver enzymes, and persisted in one (no. 5) despite the subsequent complete resolution of hepatic dysfunction. In the third patient (no. 4), liver function tests were very abnormal at diagnosis; as the steatorrhoea resolved in the context of both improvement in liver function and enzyme supplementation, the possible contribution of cholestasis to the fat malabsorption is difficult to delineate. To our knowledge, this experience brings the total number of cases of steatorrhoea reported in allograft recipients [1] [2] [3] to 11. Collectively, steatorrhoea occurred at a median of 6 months post-transplant (range 2-22). All patients had recent or concomitant active acute or chronic GVHD and responded clinically to pancreatic enzyme supplementation. In our series, three of four surviving patients had resolution of steatorrhoea as demonstrated by normalisation of faecal fat values after cessation of enzyme supplements. The improvement correlated with resolution of systemic GVHD in response to immunosuppression. The remaining patient has persistent steatorrhoea a year after therapy. These observations suggest that the damage to the exocrine pancreas is usually but not always reversible. Our current approach is to taper enzyme supplementation after 6 months of therapy in patients whose GVHD elsewhere is inactive and whose steatorrhoea has clinically resolved, monitoring the response objectively with follow-up staining stool for fat globulin and if indicated, faecal fat collections.
